Summary Conflicting reports of MDR1 gene expression in human tumours are observed according to whether studies are performed at the mRNA or P-glycoprotein level. We have investigated this expression in 22 clinically drug-resistant sarcomas at the mRNA level by Northern blot (NB), Dot blot (DB), in situ hybridisation (ISH), and at the protein level by immunohistochemistry (IHC) using three monoclonal antibodies (MoAbs): C219, JSB1, MRK16. Increased MDR1 mRNA expression was detected by NB, DB, and ISH in 1/22 sarcoma (an Ewing's sarcoma). ISH was perfectly correlated with DB hybridisation and confirmed the expression of tumoral cells alone. Specific staining of 100% of tumoral cells was obtained with the three MoAbs in the same sarcoma. Expression in tumoral cells of 12 other sarcomas was detected with MRK16, and positive staining of stromal cells with both C219 (1/22) and MRK16 (8/22) was observed. This study confirms that MDR1 overexpression occurs in human sarcomas but is not the principal mechanism of drug-resistance. Furthermore, positivity with one antibody does not necessarily imply the presence of P glycoprotein (P-gp) and a disparity may exist between the levels of P-gp and its mRNA in the same sample. So care must be taken in interpreting results and more sensitive techniques such as the polymerase chain reaction (PCR) could prove useful.
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The development of drug resistance in malignant tumours limits the effectiveness of cytotoxic drugs. This is especially true in human sarcomas which are characterised by their frequent refractoriness to chemotherapy. This problem probably implies many mechanisms of resistance. The best known, termed 'multidrug resistance' (MDR), is characterised in vitro by cross resistance to a variety of structurally unrelated drugs following exposure to one of them. The MDR phenotype is associated with increased expression of the MDR human gene known as MDR1 (Roninson et al., 1984) . This gene codes for a high molecular weight membrane glycoprotein of 170 kD: the P-glycoprotein (Pgp) (Juliano & Ling, 1976) . This membrane-associated protein is thought to act as an efflux pump extruding drugs from the cell (Safa et al., 1990) .
Human MDRl expression has been studied in a variety of normal tissues and tumours (Thiebaut et al., 1987; Goldstein et al., 1989; Cordon Cardo et al., 1990 
Materials and methods

Patients
Twenty-two patients with sarcoma diagnosed and treated at the 'Fondation Bergonie' were included in this study. In Table I (Batist et al., 1986) .
The sensitivity of all methods used was tested on MCF7 sublines with various levels of resistance to Doxorubicin: 6-fold (Adr6 MCF7), 50-fold (Adr5O MCF7) and 100-fold resistant (AdrlO0 MCF7). All these sublines were Pgp +. ISH and IHC were performed on frozen cell pellet sections of these lines.
Hybridisation probes Two probes were used: -A 3-kb cDNA EcoRl fragment corresponding to the 3' end of MDR1 cDNA. This probe, termed pAdrl, was cloned into the EcoRl-restriction site of the plasmid pGEM3 (Fairchild et al., 1987 Abbreviations: ametatasis; MFH, malignant fibrous histiocytoma; RMS, rhabdomyosarcma; LMS, leiomyosarcoma; SC, stromal cells. 'The chemotherapy used in treatment was in all cases anthracyclines associated with epipodophyllotoxines (for four patients), vinca alkaloid (for three patients), actinomycin D (for two patients).
maldehyde gel and transferred to a nylon membrane (Hybond N, Amersham) (Maniatis et al., 1982 and washed in Tris buffer saline (TBS) plus Tween. All sections were stained by an avidin-biotine peroxidase complex technique using the LSAB kit supplied by Dako (Dako, Trappes, France). C219, JSB1 and MRK16 MoAb were applied at a dilution of 1/300 for the first two and at 1/1000 for the third. A negative control consisted of sections incubated with a purified mouse IgG in place of the primary specific antibody (Sigma). All sections were examined and scores were established by two pathologists independently of the clinical data. Immunostaining was semi-quantitatively expressed as follows: the percentage of stained tumoral cells multiplied by the intensity of immunostaining evaluated from 1 to 3 (1 = weak, 2 = moderate, 3 = strong). Sensitivity of staining was tested on Adr6, Adr50 and AdrlOO MCF7 sublines. Positive staining of MCF7 Adr6 cells was demonstrated with undiluted JSB1 and MRK16 MoAb, but not with undiluted C219.
Results
Results are shown for each tumour in Table I Figure  1 confirms the specific detection of the 4.8 kb MDR1 mRNA by NB in the Adr200 MCF7 cell line and the Ewing's sarcoma, and its absence in the WT MCF7 subline. RNA ISH, first tested on MCF7 cell lines (Figure 2a ) then on the 22 sarcomas, gave similar results with positivity of the AdrR MCF7 sublines and the same Ewing's sarcoma. Several observations can be made from the Ewing's sarcoma shown in Figure 3 . High expression of the MDR1 gene, characterised by the average number of grains observed per cell, was detected in 100% of the tumoral cells, but not in the stromal or inflammatory cells. This expression was cytoplasmic and quite homogeneous from cell to cell (Figure 3, inset) (Figure 5b ). For the C219 MoAb, immunostaining
This study demonstrates a strong correlation between Dot blot and RNA in situ hybridisation methods, using the same probe (pAdrl) for evaluation of MDRl mRNA expression.
Such a correlation has previously been described (Shen et al., 1988; Bates et al., 1991) . However, sensitivity of ISH seems better than DB hybridisation since a detection threshold of MDR1 mRNA levels was obtained for the Adr6 MCF7 cell line with ISH, and for the Adr5O MCF7 subline with DB. The sensitivity of our ISH method is in agreement with previous reports showing MDR1 mRNA detection using RNA probes in breast cancer (KB-8-5) (Shen et al., 1988) and neuroblastoma (SH-SY5Y) (Bates et al., 1991) cell lines, respectively 3-fold and 4-to 6-fold resistant to Doxorubicin. The greatest value of RNA ISH is in determining MDR1 RNA expression on a cellular level and for confirming specific expression in tumoral but not stromal or inflammatory cells. We did not observe any heterogeneity of MDR1 expression by ISH in these sarcomas. This rules out the negative results of the DB hybridisation method being (Thiebaut et al., 1987; Sugawara et al., 1988; Cordon Cardo et al., 1990; Schlaifer et al., 1990; Van der Valk et al., 1990 the P-gp, and then to confirm positive results with a method such as ISH which detects MDR1 mRNA expression.
At present there are only six reports reporting MDR1 expression in human sarcomas, and findings are conflicting (Gerlach et al., 1987; Goldstein et al., 1989; Chan et al., 1990; Tawa et al., 1990; Schlaifer et al., 1990; Toffoli et al., 1992) . Three of these six reports study P-gp expression only by Western blotting or immunohistochemistry (Gerlach et al., 1987; Chan et al., 1990; Schlaifer et al., 1990) , and three study MDR1 mRNA expression only by slot or dot blot hybridisation (Goldstein et al., 1989; Tawa et al., 1990; Toffoli et al., 1992) . Our results do not agree with the findings of these other authors: they observed a more frequent overexpression of the MDR1 gene in the tumour samples they studied. Table II (Toffoli et al., 1992) , important discrepancies still remain which could be explained by the fact that we did not use the same probe nor apply the same dilutions of total RNA samples, and did not use the same cell line for positive control. So it is very difficult to compare these different results, and discrepancies are obvious. It would be advisable to study the same samples with the same methods, and for different investigators to study simultaneously MDR1 mRNA/P-glycoprotein expression. However, all investigators agree on the fact that the constitutive expression of the MDR1 gene has no effect on the primary response in untreated sarcomas (Chan et al., 1990; Toffoli et al., 1992) . The acquisition of high MDR1 mRNA/P-gp expression would be predictive of further response to chemotherapy in the course of the disease after drug treatment. Toffoli et al. did not observe any correlation between MDR1 mRNA expression and histologic grade, and DNA index or replicative activity in human sarcomas. In the literature, many cases studied present clinical chemotherapy resistance without high MDR1 mRNA/P-gp expression: 12/13 treated patients in our study, 4/12 in Toffoli et al.'s report. So neither method is sensitive enough (and PCR analysis is advisable); or else drug resistance in sarcomas could be mediated by mechanisms other than 'typical' multidrug resistance.
Finally, this study confirms that MDRl overexpression occurs in human sarcomas, but suggests that it is not the principal mechanism of drug-resistance. Given the fact that positivity with one antibody does not necessarily imply the presence of P-gp and that a disparity may exist between the levels of P-gp and its mRNA in the same sample, care must be taken in interpreting results. The evaluation of MDR1 expression by more sensitive techniques such as PCR with clinical correlation could prove useful in demonstrating the role of MDR in human sarcomas.
